Triple Therapy Shows Edge in Lung Cancer Lacking Targetable Mutations

Lung cancer remains the leading cause of cancer-related death worldwide, and one of its most stubborn forms is nonsquamous non-small cell lung cancer that carries no actionable driver gene mutation. For these patients, the revolutionary targeted therapies that transformed treatment for tumors with EGFR, ALK, or other alterations simply do not apply. Instead, oncologists rely on combinations of chemotherapy with either immune checkpoint inhibitors or antiangiogenic antibodies, and more recently on regimens that stack all three classes of drugs together. A new systematic review and network meta-analysis published in the Journal of Cancer Research and Clinical Oncology now offers one of the clearest quantitative pictures yet of how these strategies stack up against one another, and its findings are already generating discussion about how first-line treatment for this large patient population should be chosen.

The study, conducted by a team at the China-Japan Union Hospital of Jilin University in Changchun and led by corresponding authors Nanjun Hu and Lingjun Meng, set out to answer a deceptively simple question: does adding an antiangiogenic antibody to the standard pairing of immunotherapy and chemotherapy actually buy patients more time, or does it merely add toxicity without meaningful benefit? Because no single randomized trial has directly compared all three regimens head to head, the researchers turned to network meta-analysis, a statistical framework that allows indirect comparisons between treatments that have never been tested against each other in the same trial, provided they share common comparators across a network of studies.

To build that network, the team systematically searched PubMed, EMBASE, the Cochrane Library, and Web of Science from database inception through 6 January 2026. They included trials comparing triple therapy, meaning an immune checkpoint inhibitor plus an antiangiogenic antibody plus chemotherapy, against either of the two dual regimens, immune checkpoint inhibitor plus chemotherapy or antiangiogenic antibody plus chemotherapy, in patients with driver gene-negative nonsquamous non-small cell lung cancer. Five eligible studies encompassing 2,452 patients made the final cut. The primary endpoints were progression-free survival, the time patients live without their disease worsening, and overall survival, the gold standard measure of whether a treatment extends life. Secondary endpoints included the overall response rate, which captures tumor shrinkage, and the incidence of grade three or higher treatment-related adverse events, a proxy for clinically serious side effects. All analyses were performed in R software.

The headline result concerns progression-free survival. The triple regimen demonstrated significantly superior progression-free survival compared with antiangiogenic antibody plus chemotherapy alone, with a hazard ratio of 0.63 and a 95 percent confidence interval of 0.50 to 0.86. In practical terms, patients receiving the three-drug combination experienced roughly a 37 percent lower risk of disease progression or death than those on the antiangiogenic dual therapy. Against the immunotherapy-chemotherapy doublet, the triple regimen also showed an advantage, with a hazard ratio of 0.81, but the confidence interval of 0.63 to 1.1 crossed the threshold of statistical significance, meaning the difference could not be distinguished from chance with the available data.

Perhaps the most clinically consequential finding emerged from the subgroup analysis stratified by PD-L1 expression, the biomarker measured on tumor cells that is widely used to predict responsiveness to immune checkpoint blockade. In tumors with low or moderate PD-L1 expression, the analysis found no statistically significant differences between the triple and dual approaches. But in the high-expression cohort, defined as tumors with PD-L1 expression of 50 percent or more, the triple-agent regimen was significantly more effective than antiangiogenic antibody plus chemotherapy, with a hazard ratio of 0.44 and a confidence interval of 0.21 to 0.94, translating to a 56 percent reduction in the risk of progression or death. This suggests that the hottest, most immunologically inflamed tumors may be exactly where the added antiangiogenic component delivers its greatest synergistic punch, a hypothesis consistent with laboratory evidence that vascular normalization can improve immune cell infiltration into tumors.

Overall survival told a somewhat different and arguably more reassuring story for the immunotherapy-containing doublet. Compared with antiangiogenic antibody plus chemotherapy, the dual regimen of immune checkpoint inhibitor plus chemotherapy achieved significantly better overall survival, with a hazard ratio of 0.77 and a confidence interval of 0.61 to 0.98. The triple combination also beat the antiangiogenic doublet on overall survival, with a hazard ratio of 0.81 and a confidence interval of 0.67 to 0.99, a result that just reached statistical significance. Critically, however, the comparison between the two immunotherapy-containing regimens, triple versus the immunotherapy-chemotherapy doublet, was not significant for overall survival, leaving open the question of whether the extra drug genuinely extends life or merely delays progression.

On the safety front, the analysis delivered a finding that will comfort clinicians wary of intensifying first-line treatment: no significant differences were noted in the rates of grade three or higher treatment-related adverse events across the regimens. This is notable because antiangiogenic agents, which starve tumors by blocking their blood supply, carry recognized risks of hypertension, bleeding, and impaired wound healing, while immune checkpoint inhibitors can trigger autoimmune-like inflammation affecting virtually any organ. The absence of a detectable safety penalty for the triple approach in this analysis suggests that, at least across the trials included, the added toxicity burden may be manageable, though the authors and independent observers alike caution that network meta-analyses of aggregated trial data cannot capture rare adverse events or subtle quality-of-life differences the way individual patient data can.

The methodological machinery behind these conclusions deserves attention. Network meta-analysis occupies a powerful but contested space in evidence synthesis. By combining direct comparisons from trials with indirect ones inferred through shared comparators, it can rank treatments that have never met in a randomized setting, but its validity depends on the assumption that the trials being connected are sufficiently similar in patient populations, dosing, and study design. The researchers addressed this by performing an inconsistency assessment, reported in their supplementary materials, and by documenting their handling of high heterogeneity in the overall response rate endpoint, both standard safeguards designed to test whether the network’s assumptions hold. The team also reports no conflicts of interest and notes that the work was supported by the Natural Science Foundation Program of Jilin Province under grant number YDZJ202501ZYTS093.

So what should patients and oncologists take away? The authors conclude that the triple regimen of immunotherapy, antiangiogenic therapy, and chemotherapy may offer potential benefits for patients with driver gene-negative nonsquamous non-small cell lung cancer, particularly for progression-free survival, where it clearly outperformed the antiangiogenic doublet and trended toward outperforming the immunotherapy doublet. For overall survival, both immunotherapy-containing options significantly beat the antiangiogenic doublet, but neither proved superior to the other. The PD-L1 signal adds a practical decision point: for patients whose tumors express PD-L1 at 50 percent or higher, the case for the three-drug approach appears strongest, while for those with lower expression the data do not yet demand the extra agent.

Limitations temper the enthusiasm appropriately. Five trials and 2,452 patients form a relatively slender evidence base for a question of this magnitude, and the confidence interval around the triple-versus-immunotherapy-doublet comparison for progression-free survival leaves genuine uncertainty. Future randomized trials directly comparing the two immunotherapy-containing strategies, ideally with patient-level data, biomarker-driven subgroup designs, and long-term survival follow-up, will be needed to convert these network estimates into confident treatment guidelines. Until then, this analysis provides clinicians with a rigorous, quantified map of the therapeutic landscape for a patient group that has long lacked the precision options enjoyed elsewhere in lung oncology, and it reinforces a growing theme in modern cancer medicine: that rationally combining modalities that attack tumors through different biological axes, immunity, blood supply, and direct cytotoxicity, can yield dividends that no single approach achieves alone.

Subject of Research: Comparison of triple versus dual combination therapy regimens for driver gene-negative nonsquamous non-small cell lung cancer

Article Title: Efficacy and safety in triple-versus dual therapy regimens for driver gene-negative nonsquamous non-small cell lung cancer: a systematic review and network meta-analysis

Article References: Efficacy and safety in triple-versus dual therapy regimens for driver gene-negative nonsquamous non-small cell lung cancer: a systematic review and network meta-analysis. (n.d.). https://doi.org/10.1007/s00432-026-06615-5

Image Credits: AI Generated

DOI: 10.1007/s00432-026-06615-5

Keywords: lung cancer, NSCLC, immunotherapy, antiangiogenic therapy, chemotherapy, network meta-analysis, PD-L1, progression-free survival, overall survival, combination therapy, driver gene-negative, clinical oncology